A Randomized, Double-blind, Placebo-controlled Trial of Coenzyme Q10 in Huntington Disease

Objective: To test the hypothesis that chronic treatment of early-stage Huntington disease (HD) with high-dose coenzyme Q10 (CoQ) will slow the progressive functional decline of HD.

Methods: We performed a multicenter randomized, double-blind, placebo-controlled trial. Patients with early-stage HD (n = 609) were enrolled at 48 sites in the United States, Canada, and Australia from 2008 to 2012. Patients were randomized to receive either CoQ 2,400 mg/d or matching placebo, then followed for 60 months. The primary outcome variable was the change from baseline to month 60 in Total Functional Capacity score (for patients who survived) combined with time to death (for patients who died) analyzed using a joint-rank analysis approach.

Results: An interim analysis for futility revealed a conditional power of <5% for the primary analysis, prompting premature conclusion in July 2014. No statistically significant differences were seen between treatment groups for the primary or secondary outcome measures. CoQ was generally safe and well-tolerated throughout the study.

Conclusions: These data do not justify use of CoQ as a treatment to slow functional decline in HD.

Clinicaltrialsgov Identifier: NCT00608881.

Classification Of Evidence: This article provides Class I evidence that CoQ does not slow the progressive functional decline of patients with HD.

Citing Articles

Endothelial Dysfunction in Huntington's Disease: Pathophysiology and Therapeutic Implications.

Hu N, Chen Z, Zhao X, Peng X, Wu Y, Yang K Int J Mol Sci. 2025; 26(4).

PMID: 40003898 PMC: 11855594. DOI: 10.3390/ijms26041432.

Lipidomics of Huntington's Disease: A Comprehensive Review of Current Status and Future Directions.

Yilmaz A, Akyol S, Ashrafi N, Saiyed N, Turkoglu O, Graham S Metabolites. 2025; 15(1).

PMID: 39852353 PMC: 11766911. DOI: 10.3390/metabo15010010.

Nutrition and Huntington's Disease- A Review of Current Practice and Theory.

Gaba A Curr Nutr Rep. 2025; 14(1):18.

PMID: 39821731 PMC: 11739192. DOI: 10.1007/s13668-025-00610-x.

Evidence-Based Review on Symptomatic Management of Huntington's Disease.

Shin J, Yang H, Ahn J, Jo S, Chung S, Lee J J Mov Disord. 2024; 17(4):369-386.

PMID: 39117301 PMC: 11540544. DOI: 10.14802/jmd.24140.

An exploratory metabolomic comparison of participants with fast or absent functional progression from 2CARE, a randomized, double-blind clinical trial in Huntington's disease.

McGarry A, Hunter K, Gaughan J, Auinger P, Ferraro T, Pradhan B Sci Rep. 2024; 14(1):1101.

PMID: 38212353 PMC: 10784537. DOI: 10.1038/s41598-023-50553-y.

References

Beal M, Henshaw D, Jenkins B, Rosen B, Schulz J . Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann Neurol. 1994; 36(6):882-8. DOI: 10.1002/ana.410360613. View

Panov A, Gutekunst C, Leavitt B, Hayden M, Burke J, Strittmatter W . Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci. 2002; 5(8):731-6. DOI: 10.1038/nn884. View

Lodi R, Schapira A, Manners D, Styles P, Wood N, Taylor D . Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann Neurol. 2000; 48(1):72-6. View

Rosas H, Doros G, Gevorkian S, Malarick K, Reuter M, Coutu J . PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease. Neurology. 2014; 82(10):850-7. PMC: 3959748. DOI: 10.1212/WNL.0000000000000187. View

Menalled L, Patry M, Ragland N, Lowden P, Goodman J, Minnich J . Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline. PLoS One. 2010; 5(3):e9793. PMC: 2842438. DOI: 10.1371/journal.pone.0009793. View

Schilling G, Coonfield M, Ross C, Borchelt D . Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci Lett. 2001; 315(3):149-53. DOI: 10.1016/s0304-3940(01)02326-6. View

Sawa A, Wiegand G, Cooper J, Margolis R, Sharp A, Lawler Jr J . Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med. 1999; 5(10):1194-8. DOI: 10.1038/13518. View

Jenkins B, Koroshetz W, Beal M, Rosen B . Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology. 1993; 43(12):2689-95. DOI: 10.1212/wnl.43.12.2689. View

Dayalu P, Albin R . Huntington disease: pathogenesis and treatment. Neurol Clin. 2014; 33(1):101-14. DOI: 10.1016/j.ncl.2014.09.003. View

10.

Zielonka D, Mielcarek M, Landwehrmeyer G . Update on Huntington's disease: advances in care and emerging therapeutic options. Parkinsonism Relat Disord. 2015; 21(3):169-78. DOI: 10.1016/j.parkreldis.2014.12.013. View

11.

Brouillet E, Hantraye P, Ferrante R, Dolan R, Leroy-Willig A, Kowall N . Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci U S A. 1995; 92(15):7105-9. PMC: 41480. DOI: 10.1073/pnas.92.15.7105. View

12.

Matthews R, Yang L, Browne S, Baik M, Beal M . Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A. 1998; 95(15):8892-7. PMC: 21173. DOI: 10.1073/pnas.95.15.8892. View

13.

Gu M, Gash M, Mann V, Cooper J, Schapira A . Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol. 1996; 39(3):385-9. DOI: 10.1002/ana.410390317. View

14.

Browne S, Bowling A, MacGarvey U, Baik M, Berger S, Muqit M . Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol. 1997; 41(5):646-53. DOI: 10.1002/ana.410410514. View

15.

Healy B, Schoenfeld D . Comparison of analysis approaches for phase III clinical trials in amyotrophic lateral sclerosis. Muscle Nerve. 2012; 46(4):506-11. DOI: 10.1002/mus.23392. View

16.

Ross C, Aylward E, Wild E, Langbehn D, Long J, Warner J . Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014; 10(4):204-16. DOI: 10.1038/nrneurol.2014.24. View

17.

Beal M, Hyman B, Koroshetz W . Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases?. Trends Neurosci. 1993; 16(4):125-31. DOI: 10.1016/0166-2236(93)90117-5. View

18.

Dedeoglu A, Kubilus J, Yang L, Ferrante K, Hersch S, Beal M . Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J Neurochem. 2003; 85(6):1359-67. PMC: 2866522. DOI: 10.1046/j.1471-4159.2003.01706.x. View

19.

Gines S, Seong I, Fossale E, Ivanova E, Trettel F, Gusella J . Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum Mol Genet. 2003; 12(5):497-508. DOI: 10.1093/hmg/ddg046. View

20.

Ferrante R, Andreassen O, Dedeoglu A, Ferrante K, Jenkins B, Hersch S . Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci. 2002; 22(5):1592-9. PMC: 6758854. View